In the Margins
Valeant Pharmaceuticals has named Mason Morfit, a partner at activist hedge fund ValueAct Capital, to its board of directors. Morfit previously served on the embattled specialty drugmaker's board from 2007 to 2014; ValueAct is one of Valeant's largest shareholders. Read the original story from Forbes.
Most Read
Mutual fund boardrooms are more diverse than ever, with the percentage of women and individuals representing a racial or ethnic minority group increasing annually—and at a ...
Independent mutual fund directors earned more in 2022 than they did in 2021, according to industry data obtained by Fund Board Views. The year-on-year increase—a median of ...
Jay Baris, a partner in the Investment Funds group at Sidley Austin, has gotten into podcasting. The '40 Act lawyer is not just a podcast enthusiast, ...
The Securities and Exchange Commission's move away from swing pricing in the money market fund rule finalized last week was welcomed by the fund board community, ...